

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 86: Ophthalmic Agents
1Q18 January - February

Review Time Frame: November 2016 – October 2017

Background:

Ophthalmic agents are drugs used for the management of various ocular conditions and diseases in order to maintain and/or improve eye function and health.

New Drugs:

None identified.

Discontinued Drugs:

None identified.

FDA Safety Warnings:

None identified.

REVIEW RECOMMENDATION

No changes are recommended to the clinical guidance for this drug class based on the review of available clinical practice guidelines.

References:

1. Murrah MJ, DeBlock H, Erstad B et al. Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. *Crit Care Med*. 2016 Nov; 44(11):2079-2103.
2. Holz FG, Sadda SR, Staurenghi G et al. Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. *Ophthalmology*. 2017 Apr; 124(4):464-478. doi: 10.1016/j.ophtha.2016.12.002. Epub 2017 Jan 18.
3. Gale R, Scanion PH, Evans M et al. Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.
4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2015. URL: <http://www.clinicalpharmacology-ip.com/>. Updated November 2017.
5. US Food and Drug Administration. Available at: www.fda.gov. Accessed November 13, 2017.